Novoron Bioscience
Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.
Founded
2014Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.
Novoron Bioscience is a biotechnology company dedicated to developing pharmaceutical therapies aimed at regenerating the central nervous system. Founded with a mission to restore the brain and spinal cord's regenerative capacity, Novoron focuses on innovative treatments that address nerve damage and neurodegenerative diseases. Their core products are designed to enhance the natural healing processes within the central nervous system, offering new hope for patients with conditions that currently have limited treatment options.
Notable figures affiliated with Novoron include leading scientists and researchers in the field of neuroregeneration. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid development and research capabilities. Key achievements include significant advancements in preclinical studies, positioning Novoron as a promising player in the neurotherapeutics market. Overall, Novoron Bioscience is making impactful strides towards revolutionizing treatments for central nervous system injuries and diseases.
Companies similar to Novoron Bioscience include Regennova, Pipeline Therapeutics, Autobahn Therapeutics and Nora Therapeutics.
Novoron Bioscience was founded in 2014.
Novoron Bioscience's headquarters is located in San Diego, CA, US.
Novoron Bioscience's most recent funding round was for $9.5M (USD) in December 2022.
As of Dec 10, 2022, Novoron Bioscience has disclosed funding of $13.8M (USD). Undisclosed round amounts are excluded.
Novoron Bioscience has 5 employees as of Feb 5, 2024.
Nora Therapeutics
